Methods for Identifying and Using Therapeutic Agents for Raynaud's Phenomenon in Systemic Sclerosis Using Single-Cell Transcriptomic Analysis of Vascular Cell Subpopulations — USPTO Provisional Patent Specification
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Provisional patent specification (USPTO Application No. 64/007,178, filed March 16, 2026) disclosing methods for identifying therapeutic agents for Raynaud's phenomenon in systemic sclerosis using scRNA-seq vascular cell subpopulation analysis, EC subtype annotation, Raynaud's gene signature scoring, and LINCS L1000 transcriptional connectivity mapping. Priority candidates include WZ-3105 (SRC/ABL inhibitor), CGP-60474 (CDK1/2), AS-605240 (PI3K-gamma), and PD-0325901/PD-184352 (MEK1/2). Companion preprint: https://doi.org/10.5281/zenodo.19056935
Fields of Study & Subjects
Systemic Sclerosis and Related Diseases
Pulmonary Hypertension Research and Treatments
Single-cell and spatial transcriptomics
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 16 March 2026
- Language
- EN